Janney Capital analyst Ken Trbovich said in a note published on July 1 that the potential approval of Syndros was one of three potential catalysts expected in the next six months that may trigger a short squeeze in shares of Insys Therapeutics. Insys announced this morning that the FDA has approved Syndros for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. In his prior note, Trbovich set a $22 fair value estimate and Buy rating on Insys shares, which are up 20% to $16.18 in pre-market trading.